2020 European Society for Medical Oncology Conference Coverage

Every year, the European Society for Medical Oncology Congress brings together clinicians, researchers, and advocates to discuss the latest cancer study results. We’re proud to present our coverage below.

Early Results Suggest Ibrance Plus Faslodex as First Treatment Improves Outcomes for Metastatic Hormone-Receptor-Positive, HER2-Negative Breast Cancer

Studies Show Conflicting Results With Tecentriq and Chemotherapy for Metastatic Triple-Negative Breast Cancer

Adding Tecentriq to Chemotherapy Before Surgery for Early-Stage Triple-Negative Breast Cancer Improves pCR Rates

Trodelvy Improves Outcomes for Previously Treated Metastatic Triple-Negative Breast Cancer

Piqray Improves Overall Survival for Advanced-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer With PIK3CA Mutation

Adding Verzenio to Hormonal Therapy After Surgery for Early-Stage Breast Cancer With High Risk of Recurrence Reduces That Recurrence Risk

Does Chemotherapy Choice Affect How Well Tecentriq Works Against Breast Cancer?, with Leisha Emens, MD, PhD

Breast Cancer Research at ESMO 2020, with Michael Method, MD

Verzenio Reduces Recurrence Risk for Certain Early-Stage Breast Cancers, with Stephen Johnston, MD, PhD